Liquid Biopsy in Cytology - 10 Marks

Definition and Introduction

Tietz Textbook of Laboratory Medicine, 7th Edition: "The liquid biopsy approach extracts molecular information from the tumor by detailed analysis of circulating tumor-derived genetic material in the bloodstream. The sources of this material are circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and extracellular vesicles (EVs)."

1. Concept and Rationale

• Non-invasive / minimally invasive (simple blood draw)
• Can be repeated serially to monitor tumor evolution
• Captures intra-tumor heterogeneity that a single biopsy site may miss
• Detects minimal residual disease (MRD)
• Reflects contributions from both primary and metastatic sites simultaneously

Harrison's Principles of Internal Medicine 22E: "Various bodily fluids have been used for specific liquid biopsy applications to interrogate proximally associated anatomic compartments, whether using urine, feces, pleural fluid, peritoneal fluid, bronchoalveolar lavage fluid, saliva, or cerebrospinal fluid."

2. Circulating Tumor Cells (CTCs)

• CTCs represent the "seeds" of metastasis (Paget's seed and soil hypothesis, 1889)
• Their count at diagnosis correlates directly with stage and metastatic potential
• In breast cancer, ≥5 CTCs per 7.5 mL blood predicts a >6-fold increase in recurrence risk

• Prognosis: CTC count predicts progression-free survival (PFS) and overall survival (OS)
• A new staging category cM0(i+) was introduced for patients with isolated CTCs in the bone marrow
• Treatment monitoring: Serial CTC counts track therapeutic response
• Predictive marker: AR-V7-positive CTCs in castration-resistant prostate cancer predict better response to taxanes over novel hormonal agents
• CTCs detected 5 years post-diagnosis predict late breast cancer recurrence (13.1-fold higher risk)

3. Circulating Tumor DNA (ctDNA)

• Fragments of 140-170 bp in length (matching nucleosomal wrapping pattern)
• Only a few thousand amplifiable copies per mL of blood
• ctDNA fraction varies: low in early-stage cancer, high in advanced/metastatic disease

• Digital PCR (dPCR): Highly sensitive, detects known mutations (e.g., KRAS, EGFR)
• Tagged-Amplicon Deep Sequencing (TAm-Seq): Amplifies and deeply sequences thousands of bases from individual fragmented DNA copies
• Next-Generation Sequencing (NGS) / Massively Parallel Sequencing (MPS): Detects hundreds of mutations simultaneously; allows tumor mutational burden (TMB) assessment
• BEAMing (Beads, Emulsification, Amplification, Magnetics): Mutation detection at allele frequencies <0.01%
• CancerSEEK: Combines ctDNA mutations with protein biomarkers to detect and locate early-stage cancer

• Early detection / cancer screening
• Companion diagnostics (e.g., EGFR mutations for NSCLC TKI therapy)
• MRD monitoring post-surgery
• Detection of acquired resistance mutations (e.g., T790M in EGFR-mutant NSCLC)
• Organ-of-origin determination for cancers of unknown primary

Emery's Elements of Medical Genetics and Genomics: "The frequency of CTCs and ctDNA in plasma correlates with the stage of cancer in the patient - the more advanced the cancer, the higher the frequency of CTC and ctDNA; this also correlates with survival."

4. Extracellular Vesicles - Exosomes

• DNA (including double-stranded DNA)
• mRNA and non-coding RNAs (miRNA, lncRNA)
• Proteins (oncoproteins, enzymes, receptors)
• Lipids

• Protected from nuclease degradation by lipid bilayer membrane
• Reflect active tumor biology, not just dying cells
• Carry protein markers alongside nucleic acids, enabling multi-analyte analysis

• Cancer diagnosis and staging
• Drug resistance mechanisms
• Tumor microenvironment communication (CTCs interact with platelets and macrophages via exosomes)
• Exosomes from tumor cells can prepare distant "pre-metastatic niches"

5. Circulating miRNAs

• Highly stable in blood (protected by exosomes or protein complexes)
• Tumor-type specific expression patterns
• Detectable in serum, plasma, urine, saliva

• miR-21: Upregulated in many cancers (colon, breast, lung)
• miR-141: Elevated in metastatic prostate cancer
• miR-155: Associated with hematological malignancies
• miR-210: Hypoxia-induced; associated with poor prognosis

6. Platforms and Technologies in Cytology

• Standard for CTC enumeration
• EpCAM immunomagnetic enrichment → staining with CK8/18/19 (epithelial markers), DAPI (nuclei), CD45 (leukocyte exclusion)
• Defines a CTC as: EpCAM+, CK+, DAPI+, CD45-

• CTC-chip / Herringbone chip: Microchannels coated with EpCAM antibodies; captures CTCs from whole blood with high efficiency
• Spiral chip: Uses Dean flow forces (size-based separation)

• Allows detection of specific chromosomal abnormalities (e.g., HER2 amplification, AR-V7 status in prostate cancer CTCs)
• Padlock probe technology enables in situ RNA analysis in single CTCs

• Dielectrophoresis-based single-cell isolation
• Allows single CTC retrieval for subsequent single-cell sequencing

7. Clinical Applications

• CellSearch (CTC) is FDA-cleared for breast, colorectal, and prostate cancer
• Plasma EGFR ctDNA testing is FDA-approved for NSCLC treatment selection
• Guardant360, FoundationOne Liquid CDx are FDA-approved ctDNA NGS panels

8. Liquid Biopsy in Specific Cancers

• EGFR mutations (exon 19 del, L858R, T790M) in plasma ctDNA guide first-line and second-line TKI therapy
• Relevant when tissue biopsy is insufficient or impossible

• CTCs ≥5 per 7.5 mL blood = poor prognosis in metastatic breast cancer
• PIK3CA, ESR1 mutations in ctDNA guide CDK4/6 inhibitor and fulvestrant therapy
• CTC detection 5 years post-diagnosis predicts late recurrence

• KRAS, NRAS, BRAF mutations in ctDNA guide anti-EGFR therapy
• Post-operative ctDNA positivity predicts recurrence

• AR-V7-positive CTCs: resistance to enzalutamide/abiraterone; better response to taxanes
• ctDNA monitors androgen receptor amplification

• BCR-ABL1 fusion transcript monitoring in CML (using liquid biopsy from peripheral blood)
• MRD monitoring using PCR / NGS

9. Comparison: Liquid Biopsy vs. Tissue Biopsy

Tietz Textbook of Laboratory Medicine, 7th Edition: "Both types of liquid biopsy assays need better quality control and standardization to provide more consistent reporting and comparisons... Both approaches provide overlapping information and unique information for specific cancers."

10. Limitations and Future Challenges

1. Low sensitivity in early-stage disease: ctDNA may be undetectable when tumor burden is minimal (stages I-II)
2. Lack of standardization: Pre-analytical variables (tube type, processing time, temperature) significantly affect ctDNA yields; no universal standard protocols exist
3. Technical challenges: Low allele frequency of somatic mutations requires ultra-sensitive assays; false positives from clonal hematopoiesis of indeterminate potential (CHIP)
4. CTC heterogeneity: EpCAM-negative CTCs (due to epithelial-mesenchymal transition/EMT) are missed by EpCAM-based platforms
5. Interpretation complexity: Variant of uncertain significance (VUS) calls in NGS panels require expert bioinformatic analysis
6. No tissue confirmation: Cannot replace histological/cytological diagnosis for primary tumor characterization
7. Regulatory approval gaps: Most applications remain research-use-only; limited FDA-cleared assays

• Multi-analyte panels (CancerSEEK approach): Combined ctDNA + protein biomarkers for early detection with organ-of-origin prediction
• Single-cell CTC sequencing: Full genomic/transcriptomic profiling of individual CTCs
• cfRNA and fragmentomics: Nucleosomal positioning patterns of cfDNA fragments to infer tissue of origin
• Epigenetic liquid biopsy: cfDNA methylation profiling for cancer type-specific detection (GRAIL/Galleri test)
• International guidelines via ELBS (European Liquid Biopsy Society) and CAP proficiency testing programs for standardization

Harrison's Principles of Internal Medicine 22E (2025): "Tumors are well known to release analytes into body fluids... an approach to analyze cancer less invasively, such as from a blood sample, serves as a potentially attractive alternative in the clinical evaluation of patients with cancer."

Summary Table: Components of Liquid Biopsy

• Tietz Textbook of Laboratory Medicine, 7th Ed. - Chapter 71 (Liquid Biopsy)
• Harrison's Principles of Internal Medicine, 22nd Ed. - Chapter 503 (Circulating Nucleic Acids as Liquid Biopsies)
• Robbins & Kumar Basic Pathology (Liquid Biopsy, Ch. 4)
• Emery's Elements of Medical Genetics and Genomics (Circulating Tumor DNA)
• Recent literature: Ma L et al. Signal Transduct Target Ther 2024 [PMID: 39617822]; Dai CS et al. Cancer Cell 2025 [PMID: 40749671]